At a Glance
Quickcomparison
Dose Range
Relaxin-2 (Serelaxin)
1–10 mcg
BPC-157
250–500 mcg
Frequency
Once daily
Administration
Intravenous (IV) infusion
Subcutaneous injection
Cycle Length
8-12 weeks
4-6 weeks
Onset Speed
Moderate (1-2 weeks)
Evidence Level
Limited human trials
Strong preclinical (extensive animal studies)
Efficacy
Benefitratings
Cardiovascular Function
Heart Failure Support
Acute Medical Management
Primary Benefit
Secondary Benefit
Additional Benefit
Technical Data
Compoundspecifications
Molecular Formula
C256H408N74O74S8
Molecular Weight
5,963 Da (Daltons)
Half-Life
Varies by route of administration
Bioavailability
CAS Number
See PubChem for identifiers
C62H98N16O22
1419.53 g/mol
4-6 hours
~100% (subcutaneous)
137525-51-0
Protocols
Dosingtiers
standard
30 mcg/kg/day
Continuous IV infusion
48 hours
Weight-adjusted continuous IV infusion used across the RELAX-AHF programme for acute heart failure; improved dyspnea but did not reduce mortality in RELAX-AHF-2 [3][5]. Hospital administration only.
starting
250 mcg
1-2 weeks
A common starting amount in research practice, often injected near the injured area. BPC-157 has no human dose-finding trials, so doses come from animal studies and documented practice [1][2].
250-500 mcg
Twice daily
Commonly used range for tissue and tendon recovery in research practice [1][3].
advanced
500 mcg
6-8 weeks
Upper end used in practice for more demanding acute injuries [1][3].
Applications
Bestsuited for
Acute heart failure symptom management
Relaxin-2 (Serelaxin) is particularly effective for individuals focused on acute heart failure symptom management. Research supports its use in this area.
Cardiovascular recovery and support
Relaxin-2 (Serelaxin) is particularly effective for individuals focused on cardiovascular recovery and support. Research supports its use in this area.
Hospital-based therapeutic interventions
Relaxin-2 (Serelaxin) is particularly effective for individuals focused on hospital-based therapeutic interventions. Research supports its use in this area.
Tendon and ligament injuries
Sprains, strains, tears, tendinitis - BPC-157 accelerates collagen synthesis and tissue repair
Gut healing
IBS, leaky gut, ulcers, inflammatory bowel conditions - derived from gastric juice, it has a natural affinity for digestive tissue
Muscle injuries
Strains, post-workout recovery, chronic muscle issues - promotes angiogenesis and growth factor expression
Joint problems
Arthritis support, joint pain, cartilage issues - anti-inflammatory and regenerative properties
Post-surgical recovery
Accelerating healing after procedures - works systemically to enhance the body's repair mechanisms
Safety Profile
Sideeffects
Common
Hypotension (low blood pressure) - most common
Tachycardia (increased heart rate)
Headache
Nausea
Dizziness
Peripheral edema (swelling)
Increased creatinine levels
Hyperkalemia (high potassium)
Syncope (fainting)
Atrial fibrillation
Blood pressure checks every 2-4 hours during infusion
Kidney function (creatinine and eGFR)
Electrolytes, particularly potassium
Heart rate and cardiac rhythm
Urine output
Serious
Severe cardiovascular events
Injection site redness
Mild nausea
Uncommon
Fatigue
Hot/cold sensations
Allergic reaction
Research Status
Safety& evidence
FDA Status
Research compound
Safety Overview
Serelaxin (recombinant relaxin-2) completed Phase III heart failure trials with favorable safety profile and cardiovascular benefit signals. Hypotension occurs in 20-25% of subjects requiring hemodynamic monitoring; no serious adverse events directly attributable to serelaxin beyond expected vasodilatory effects. Flushing and headaches mild and transient. No serious immunogenicity despite being recombinant human peptide; repeat dosing shows consistent response.
Contraindications
xSevere hypotension or hemodynamic instability
xPregnancy (despite relaxin's natural role)
xAcute kidney injury or severe renal dysfunction
xRecent myocardial infarction (within 7 days)
xUncontrolled arrhythmias
BPC-157 is a gastric pentadecapeptide with strong preclinical evidence from extensive animal studies spanning over 25 years of research. Critical limitation: BPC-157 has NOT completed Phase 3 human clinical trials. No FDA approval exists. Safety data comes primarily from rat and mouse studies, with only limited Phase 1-2 human data. Animal studies show no toxicity at therapeutic doses, but human data is insufficient for regulatory approval. The peptide is unregulated, and no standardized manufacturing or quality control requirements exist for research compounds. Individual responses may vary significantly, and serious medical supervision is essential before use, particularly if you have gastrointestinal conditions, take medications, or have pre-existing medical conditions.
xPregnancy
xBreastfeeding
xActive cancer
xHistory of cancer
Decision Guide
Which isright for you?
Choose Relaxin-2 (Serelaxin) if...
Acute heart failure symptom management
Cardiovascular recovery and support
Hospital-based therapeutic interventions
Choose BPC-157 if...
Injury recovery
Post-surgery healing
Chronic pain management
Gut health